Although B-Raf and MEK inhibitors are actively used for the treatment of metastatic melanoma in patients with B-RafV600E mutations, the development of resistance to these drugs has limited their therapeutic utilization in such patients. The gene discussed is MAP2K7; the disease is metastatic melanoma.